Skip to main content

Sierra Oncology Stock Forecast, Price & News

+0.19 (+1.08 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,561 shs
Average Volume30,994 shs
Market Capitalization$219.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

Sierra Oncology logo

About Sierra Oncology

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
Phone(604) 558-6536
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$8.93 per share


Net Income$-88,280,000.00




Market Cap$219.71 million
Next Earnings Date8/5/2021 (Estimated)


Overall MarketRank

1.85 out of 5 stars

Medical Sector

132nd out of 2,032 stocks

Pharmaceutical Preparations Industry

51st out of 768 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

Is Sierra Oncology a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sierra Oncology stock.
View analyst ratings for Sierra Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Sierra Oncology?

Wall Street analysts have given Sierra Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sierra Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 29,100 shares, an increase of 20.2% from the March 31st total of 24,200 shares. Based on an average daily trading volume, of 33,200 shares, the short-interest ratio is currently 0.9 days. Currently, 0.5% of the shares of the stock are sold short.
View Sierra Oncology's Short Interest

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Sierra Oncology

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings data on Thursday, March, 11th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.52) by $0.11. The biotechnology company had revenue of $0.20 million for the quarter.
View Sierra Oncology's earnings history

How has Sierra Oncology's stock price been impacted by Coronavirus (COVID-19)?

Sierra Oncology's stock was trading at $11.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRRA shares have increased by 53.4% and is now trading at $17.79.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SRRA?

3 Wall Street analysts have issued 12-month target prices for Sierra Oncology's shares. Their forecasts range from $27.00 to $29.00. On average, they anticipate Sierra Oncology's share price to reach $28.00 in the next year. This suggests a possible upside of 57.4% from the stock's current price.
View analysts' price targets for Sierra Oncology
or view top-rated stocks among Wall Street analysts.

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the following people:
  • Dr. Stephen G. Dilly MBBS, Ph.D., Pres, CEO & Director (Age 61, Pay $778.95k)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 64, Pay $706.25k)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 66, Pay $629.03k)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 47)
  • Ms. Christina Thomson M.S., J.D., Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. William D. Turner, Chief Regulatory & Technical Operations Officer (Age 55)
  • Mr. Kevin Norrett M.B.A., M.S., Chief Bus. Officer (Age 48)

Who are some of Sierra Oncology's key competitors?

What other stocks do shareholders of Sierra Oncology own?

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (8.24%), Ikarian Capital LLC (3.60%), Renaissance Technologies LLC (0.87%), Pura Vida Investments LLC (0.63%), Northern Trust Corp (0.15%) and Dimensional Fund Advisors LP (0.14%).
View institutional ownership trends for Sierra Oncology

Which major investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for Sierra Oncology
or view top insider-selling stocks.

Which major investors are buying Sierra Oncology stock?

SRRA stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Ikarian Capital LLC, Pura Vida Investments LLC, Dimensional Fund Advisors LP, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Sierra Oncology
or or view top insider-buying stocks.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $17.79.

How much money does Sierra Oncology make?

Sierra Oncology has a market capitalization of $219.71 million. The biotechnology company earns $-88,280,000.00 in net income (profit) each year or ($19.52) on an earnings per share basis.

How many employees does Sierra Oncology have?

Sierra Oncology employs 69 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is

Where are Sierra Oncology's headquarters?

Sierra Oncology is headquartered at 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at (604) 558-6536 or via email at [email protected]

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.